⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVCT News
Nuvectis Pharma, Inc. Common Stock
Form 8-K
sec.gov
NVCT
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
globenewswire.com
NVCT
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
globenewswire.com
NVCT
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
globenewswire.com
NVCT
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
globenewswire.com
NVCT
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
globenewswire.com
NVCT
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
globenewswire.com
NVCT
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
globenewswire.com
NVCT
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
globenewswire.com
NVCT
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
globenewswire.com
NVCT